vs

Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and FIRST UNITED CORP (FUNC). Click either name above to swap in a different company.

FIRST UNITED CORP is the larger business by last-quarter revenue ($23.2M vs $13.5M, roughly 1.7× Assertio Holdings, Inc.). On growth, FIRST UNITED CORP posted the faster year-over-year revenue change (11.9% vs -57.9%). Over the past eight quarters, FIRST UNITED CORP's revenue compounded faster (11.5% CAGR vs -35.4%).

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

United Breweries Holdings Limited (UBHL), also called UB Group, is the Indian subsidiary of Heineken N.V.. It is headquartered in UB City, Bangalore, Karnataka. Its core business includes beverages and investments in various sectors. The company markets beer under the Kingfisher brand, and owns various other brands of alcoholic beverages. United Breweries is India's largest producer of beer.

ASRT vs FUNC — Head-to-Head

Bigger by revenue
FUNC
FUNC
1.7× larger
FUNC
$23.2M
$13.5M
ASRT
Growing faster (revenue YoY)
FUNC
FUNC
+69.8% gap
FUNC
11.9%
-57.9%
ASRT
Faster 2-yr revenue CAGR
FUNC
FUNC
Annualised
FUNC
11.5%
-35.4%
ASRT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASRT
ASRT
FUNC
FUNC
Revenue
$13.5M
$23.2M
Net Profit
$5.8M
Gross Margin
Operating Margin
-86.7%
32.9%
Net Margin
24.9%
Revenue YoY
-57.9%
11.9%
Net Profit YoY
-6.6%
EPS (diluted)
$-4.54
$0.89

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASRT
ASRT
FUNC
FUNC
Q4 25
$13.5M
$23.2M
Q3 25
$49.5M
$22.7M
Q2 25
$29.2M
$21.8M
Q1 25
$26.5M
$20.9M
Q4 24
$32.2M
$20.8M
Q3 24
$29.2M
$20.3M
Q2 24
$31.1M
$20.1M
Q1 24
$32.4M
$18.7M
Net Profit
ASRT
ASRT
FUNC
FUNC
Q4 25
$5.8M
Q3 25
$11.4M
$6.9M
Q2 25
$-16.4M
$6.0M
Q1 25
$-13.5M
$5.8M
Q4 24
$6.2M
Q3 24
$-2.9M
$5.8M
Q2 24
$-3.7M
$4.9M
Q1 24
$-4.5M
$3.7M
Operating Margin
ASRT
ASRT
FUNC
FUNC
Q4 25
-86.7%
32.9%
Q3 25
23.2%
40.6%
Q2 25
-27.5%
36.5%
Q1 25
-50.0%
36.8%
Q4 24
-41.9%
39.2%
Q3 24
-10.4%
38.0%
Q2 24
-11.6%
32.5%
Q1 24
-13.4%
26.0%
Net Margin
ASRT
ASRT
FUNC
FUNC
Q4 25
24.9%
Q3 25
23.1%
30.6%
Q2 25
-56.0%
27.5%
Q1 25
-51.1%
27.7%
Q4 24
29.8%
Q3 24
-10.0%
28.5%
Q2 24
-11.8%
24.5%
Q1 24
-13.9%
19.8%
EPS (diluted)
ASRT
ASRT
FUNC
FUNC
Q4 25
$-4.54
$0.89
Q3 25
$0.11
$1.07
Q2 25
$-0.17
$0.92
Q1 25
$-0.14
$0.89
Q4 24
$-3.28
$0.95
Q3 24
$-0.03
$0.89
Q2 24
$-0.04
$0.75
Q1 24
$-0.05
$0.56

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASRT
ASRT
FUNC
FUNC
Cash + ST InvestmentsLiquidity on hand
$63.4M
$131.6M
Total DebtLower is stronger
$95.9M
Stockholders' EquityBook value
$94.0M
$203.6M
Total Assets
$267.0M
$2.1B
Debt / EquityLower = less leverage
0.47×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASRT
ASRT
FUNC
FUNC
Q4 25
$63.4M
$131.6M
Q3 25
$93.4M
$95.2M
Q2 25
$98.2M
$79.1M
Q1 25
$87.3M
$84.4M
Q4 24
$100.1M
$78.3M
Q3 24
$88.6M
$62.4M
Q2 24
$88.4M
$45.1M
Q1 24
$80.7M
$86.9M
Total Debt
ASRT
ASRT
FUNC
FUNC
Q4 25
$95.9M
Q3 25
$95.9M
Q2 25
$120.9M
Q1 25
$120.9M
Q4 24
$120.9M
Q3 24
$120.9M
Q2 24
$70.9M
Q1 24
$38.6M
$70.9M
Stockholders' Equity
ASRT
ASRT
FUNC
FUNC
Q4 25
$94.0M
$203.6M
Q3 25
$105.8M
$199.1M
Q2 25
$93.3M
$191.1M
Q1 25
$108.5M
$183.7M
Q4 24
$121.1M
$179.3M
Q3 24
$130.5M
$174.0M
Q2 24
$132.2M
$164.2M
Q1 24
$134.5M
$165.5M
Total Assets
ASRT
ASRT
FUNC
FUNC
Q4 25
$267.0M
$2.1B
Q3 25
$319.8M
$2.0B
Q2 25
$273.8M
$2.0B
Q1 25
$286.4M
$2.0B
Q4 24
$284.7M
$2.0B
Q3 24
$276.0M
$1.9B
Q2 24
$279.4M
$1.9B
Q1 24
$282.0M
$1.9B
Debt / Equity
ASRT
ASRT
FUNC
FUNC
Q4 25
0.47×
Q3 25
0.48×
Q2 25
0.63×
Q1 25
0.66×
Q4 24
0.67×
Q3 24
0.70×
Q2 24
0.43×
Q1 24
0.29×
0.43×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASRT
ASRT
FUNC
FUNC
Operating Cash FlowLast quarter
$-30.0M
$19.4M
Free Cash FlowOCF − Capex
$15.4M
FCF MarginFCF / Revenue
66.3%
Capex IntensityCapex / Revenue
17.1%
Cash ConversionOCF / Net Profit
3.35×
TTM Free Cash FlowTrailing 4 quarters
$22.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASRT
ASRT
FUNC
FUNC
Q4 25
$-30.0M
$19.4M
Q3 25
$-4.8M
$1.5M
Q2 25
$19.1M
$995.0K
Q1 25
$-12.5M
$7.0M
Q4 24
$11.5M
$22.3M
Q3 24
$-35.0K
$2.3M
Q2 24
$7.4M
$7.2M
Q1 24
$7.5M
$3.6M
Free Cash Flow
ASRT
ASRT
FUNC
FUNC
Q4 25
$15.4M
Q3 25
$168.0K
Q2 25
$706.0K
Q1 25
$6.4M
Q4 24
$20.4M
Q3 24
$588.0K
Q2 24
$7.0M
Q1 24
$3.5M
FCF Margin
ASRT
ASRT
FUNC
FUNC
Q4 25
66.3%
Q3 25
0.7%
Q2 25
3.2%
Q1 25
30.5%
Q4 24
98.1%
Q3 24
2.9%
Q2 24
35.1%
Q1 24
18.9%
Capex Intensity
ASRT
ASRT
FUNC
FUNC
Q4 25
17.1%
Q3 25
5.9%
Q2 25
1.3%
Q1 25
2.8%
Q4 24
9.3%
Q3 24
0.0%
8.4%
Q2 24
0.6%
Q1 24
0.3%
Cash Conversion
ASRT
ASRT
FUNC
FUNC
Q4 25
3.35×
Q3 25
-0.42×
0.22×
Q2 25
0.17×
Q1 25
1.20×
Q4 24
3.60×
Q3 24
0.40×
Q2 24
1.46×
Q1 24
0.97×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

FUNC
FUNC

Trust Department$9.8M42%
Other$5.6M24%
Debit Card Income$4.1M17%
Service Charges$2.3M10%
Brokerage Commissions$1.4M6%

Related Comparisons